1. In Vivo

The Renal Denervation Buzz: Separating Fact From Myth; Covidien Buys Maya Medical

Renal denervation was clearly the belle of this year’s EuroPCR, with more than a dozen sessions on the topic. In addition, just preceding the meeting, Covidien announced its acquisition of RDN start-up Maya Medical.

This year’s EuroPCR conference, held in Paris in May, was definitely the coming out party for renal denervation (RDN), highlighting what many clinicians and industry executives point to as the next potential blockbuster device product market. In that way, RDN is following in the footsteps of transcatheter aortic valves (TAVI) and drug-eluting stents (DES), both of which were unveiled at previous EuroPCR meetings and remain important topics today, with numerous sessions on both at this year’s conference.

But renal denervation was clearly the belle of this year’s EuroPCR, with more than a dozen sessions on the topic...

More from Archive

More from In Vivo

Podcast: ADDF’s Karen Harris On Investing In Alzheimer’s Like A VC

 
• By David Wild

A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By Ashley Yeo

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By David Wild

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.